Publications

Journal Article
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Epublish 20 citations
Electronic publication date
November 26, 2019

View on Pubmed.gov 30006637 | View on doi.org 10.1038/s41598-...

Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance.

Search for publications in this journal Sci Rep - 8(1):10652

Abstract

Therapy of Burkholderia pseudomallei acute infections is largely limited to a few β-lactam antibiotics such as ceftazidime or meropenem. Although relatively rare, resistance emergence during therapy leads to treatment failures with high mortality rates. In the absence of acquired external resistance determinants in B. pseudomallei emergence of β-lactam resistance is invariably caused by mutational modification of genomically encoded factors. These include the deletion of the ceftazidime target penicillin-binding protein 3 or amino acid changes in the Class A PenA β-lactamase that expand its substrate spectrum, as well as penA gene duplication and amplification or its overexpression via transcriptional up-regulation. Evidence is presented that penA is co-transcribed with the upstream nlpD1 gene, that the transcriptional terminator for nlpD1 serves as a penA attenuator and that generation of a new promoter immediately upstream of the terminator/attenuator by a conserved G to A transition leads to anti-termination and thus constitutive PenA expression and extended β-lactam resistance. Further evidence obtained with the extensively β-lactam resistant clinical isolate Bp1651 shows that in addition to PenA overexpression and structural mutations other adaptive mechanisms contribute to intrinsic and acquired B. pseudomallei β-lactam resistance.

References

mBio. 2013 Nov 05;4(6):e00604-13

PLoS One. 2012;7(5):e37585

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6557-6562

Emerg Infect Dis. 2012 Dec;18(12):e2

Cited by 20 citations (total)

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei.

Electronic publication date June 19, 2023

Search for publications in this journal Antimicrob Agents Chemother

Carina M Hall [...] Herbert P Schweizer et al.

Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei...

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria.

Electronic publication date February 12, 2021

Search for publications in this journal mBio

Nawarat Somprasong [...] Herbert P Schweizer et al.

, the founding member of the complex (Bpc), is a biothreat agent and causes melioidosis, a disease whose treatment...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances